重组大肠杆菌将胆绿素生物转化以合成胆红素。
Recombinant Escherichia coli biotransformation of biliverdin to synthesize bilirubin.
作者信息
Zhang Yue, Luan Haoni, Qiu Wenhan, Xu Wei, Feng Wei, Wang Fei, Song Peng
机构信息
School of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China.
State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, Liaocheng, China.
出版信息
World J Microbiol Biotechnol. 2025 Aug 26;41(9):315. doi: 10.1007/s11274-025-04527-z.
Bilirubin, a heme-derived metabolite with pronounced bioactivity, exhibits significant potential for pharmaceutical applications. This study developed a recombinant Escherichia coli-based biliverdin biotransformation system, enabling efficient bilirubin synthesis via heterologous expression of a novel biliverdin reductase (BvdR', XP_032760038.1) from Rattus norvegicus and a glucose dehydrogenase (GDH) from Priestia megaterium. Under optimized conditions (520 mg/L biliverdin, pH 7.5, 37 °C), the system achieved a biliverdin conversion rate of 99.2% and a bilirubin yield of 89.9%. The integration of an NADPH in situ regeneration system significantly reduced synthesis costs, providing a novel strategy for scalable bilirubin production.
胆红素是一种具有显著生物活性的血红素衍生代谢物，在药物应用方面具有巨大潜力。本研究开发了一种基于重组大肠杆菌的胆绿素生物转化系统，通过异源表达来自褐家鼠的新型胆绿素还原酶（BvdR'，XP_032760038.1）和来自巨大芽孢杆菌的葡萄糖脱氢酶（GDH），实现了胆红素的高效合成。在优化条件（520 mg/L胆绿素，pH 7.5，37°C）下，该系统的胆绿素转化率达到99.2%，胆红素产量达到89.9%。NADPH原位再生系统的整合显著降低了合成成本，为规模化生产胆红素提供了一种新策略。
Zotero 插件